Related Announcements

PAR-20-155, "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)"

NOT-EB-21-032: "Notice of NIBIB Withdrawal from PAR-21-166, "Academic-Industrial Partnerships of Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)"

NOT-EB-21-023: "Notice of Intent to Publish a Funding Opportunity Announcement for Bioengineering Partnership with Industry (BPI) (U01 Clinical Trial Optional)"

Issued by

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Purpose

Effective immediately, National Institute of Biomedical Imaging and Bioengineering (NIBIB) withdraws its participation in PAR-20-155, "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)."

Projects within the NIBIB mission that incorporate academic-industrial partnerships may be suitable for the Bioengineering Partnership with Industry (BPI) initiative (NOT-EB-21-023).

Inquiries

Please direct all inquiries to:

I. George Zubal, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-827-5168
Email: [email protected]